HEALTH OF WOMAN. 2020.9-10(155-156): 76-82

Affiliation

1. West China Hospital, Sichuan University, Chengdu, Sichuan, China.
2. Clinical Research Centre, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
3. West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
4. University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh, PA, USA.
5. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
6. Department of Surgery, Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.

REFERENCES

1. Everett C. 1997, Jul 5. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ (Clinical research ed). 315(7099):32-4.

2. Mesiano S, Wang Y, Norwitz ER. 2011, Jan. Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reproductive sciences (Thousand Oaks, Calif). 18(1):6-19.

3. Verhaegen J, Gallos ID, van Mello NM, Abdel-Aziz M, Takwoingi Y, Harb H et al. 2012, Sep 27. Accuracy of single progesterone test to predict early pregnancy outcome in women with pain or bleeding: meta-analysis of cohort studies. BMJ (Clinical research ed). 345:e6077.

4. Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B. 1987. Double-blind controlled trial of progesterone substitution in threatened abortion. Biological research in pregnancy and perinatology 8(1 1ST Half):26-34.

5. Palagiano A, Bulletti C, Pace MC, D DEZ, Cicinelli E, Izzo A. 2004, Dec. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann N Y Acad Sci. 1034:200-10.

6. Omar MH, Mashita MK, Lim PS, Jamil MA. 2005. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 97:421-5.

7. El-Zibdeh MY, Yousef LT. 2009. Dydrogesterone support in threatened miscarriage. Maturitas 65; Suppl 1:S43-S46.

8. Pandian RU. 2009, Dec. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 65; Suppl 1:S47-50.

9. Alimohamadi S, Javadian P, Gharedaghi MH, Javadian N, Alinia H, Khazardoust S et al. 2013, Jun. Progesterone and threatened abortion: a randomized clinical trial on endocervical cytokine concentrations. J Reprod Immunol 98(1-2):52-60.

10. Yassaee F, Shekarriz-Foumani R, Afsari S, Fallahian M. 2014. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. J Reprod Infertil 15(3):147-51.

11. Turgal M, Aydin E, Ozyuncu O. 2017. Effect of micronized progesterone on fetal-placental volume in first-trimester threatened abortion. J Clin Ultrasound 45(1):14-9.

12. Lee HJ, Park TC, Kim JH, Norwitz E, Lee B. 2017. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. BioMed Research International. 2017:3616875.

13. Wahabi HA, Fayed AA, Esmaeil SA, Bahkali KH. 2018, Aug 6. Progestogen for treating threatened miscarriage. The Cochrane Database of Systematic Reviews. 8:CD005943.

14. Gynecologists ACoOa. ACOG practice bulletin-clinical management guidelines for obstetricians-gynecologists: early pregnancy loss. May 2015: https://www.acog.org/-/media/Practice-Bulletins/Committee-on-Practice-Bulletins—-Gynecology/ Public/pb150.pdf

15. Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID et al. 2019, May 9. A randomized trial of progesterone in women with bleeding in early pregnancy. The New England journal of medicine. 380(19):1815-24.

16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. 2009, Aug 18. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine. 151(4):W65-94.

17. Shinichi A. 2014. Cochrane handbook for systematic reviews of interventions. Online Kensaku 35(3):154-5.

18. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. 2008, Apr 26. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed). 336(7650):924-6.

19. Higgins JP, Thompson SG. 2002, Jun 15. Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-58.

20. Egger M, Davey Smith G, Schneider M, Minder C. 1997, Sep 13. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed ). 315 97109):629-34.

21. Brok J, Thorlund K, Gluud C, Wetterslev J. 2008, Aug. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 61(8):763-9.

22. Ehrenskjold ML, Bondo B, Weile F. 1967, Dec 14. Treatment of threatened abortion with dydrogesterone. Ugeskr Laeger 129(50):1678-9.

23. Czajkowski K, Sienko J, Mogilinski M, Bros M, Szczecina R, Czajkowska A. 2007, Mar. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril 87(3):613-8.

24. Vincze E, Molna´rGB, Fo¨ldesiPlA. 2006. Treatment possibilities for threatened abortion using progesterone and progesterone-type drugs. Magyar Noorvosok Lapja 69:281-4.

25. Siew JYS, Allen JC, Hui CYY, Ku CW, Malhotra R, Ostbye T et al. 2018, Sep. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 228:319-24.

26. Darwish A. 2012. Enhancing Success of Assisted Reproduction. Rijeka: InTech.:155-72.

27. Mirza FG, Patki A, Pexman-Fieth C. 2016. Dydrogesterone use in early pregnancy. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 32(2):97-106.

28. Merriam KS, Leake KA, Elliot M, Matthews ML, Usadi RS, Hurst BS. 2015. Sexual absorption of vaginal progesterone: a randomized control trial. Int J Endocrinol 2015:685281.